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ABSTRACT 
 
Background The 7-valent (PCV7) and 13-valent (PCV13) pneumococcal conjugate vaccines are 
highly effective in preventing invasive pneumococcal disease (IPD) caused by vaccine serotypes. 
Vaccine failure (vaccine-type IPD after age-appropriate immunisation) is rare. Little is known about 
the risk, clinical characteristics or outcomes of PCV13 compared to PCV7 vaccine failure.  
Methods Public Health England conducts IPD surveillance and provides a national reference 
service for serotyping pneumococcal isolates in England and Wales. We compared the 
epidemiology, rates, risk factors, serotype distribution, clinical characteristics, and outcomes of IPD 
in children with PCV13 and PCV7 vaccine failure.    
Results A total of 163 episodes of PCV failure were confirmed in 161 children over eight years (04 
September 2006 to 03 September 2014) in ten birth cohorts. After three vaccine doses, PCV7 and 
PCV13 failure rates were 0.19/100,000 (95% CI, 0.10-0.33; 57 cases) and 0.66/100,000 (95% CI, 
0.44-0.99; 104 cases) vaccinated person-years, respectively. Children with PCV13 failure were 
more likely to be healthy (87/105 [82.9%] vs. 37/56 [66.1%]; P=0.02), present with bacteremic lower 
respiratory tract infection (61/105 [58.1%] vs. 11/56 [19.6%]; P<0.001) and develop empyema 
(41/61 [67.2%] vs. 1/11 [9.1%]; P<0.001) compared to PCV7 failures. Serotypes 3 (n=38, 36.2%) 
and 19A (n=30, 28.6%) were responsible for most PCV13 failures. Five children died (3.1%; 95% 
CI, 1.0-7.1%), including four with co-morbidities.  
Conclusions PCV failure is rare and, compared to PCV7 serotypes, the additional PCV13 
serotypes are more likely to cause bacteremic lower respiratory tract infection and empyema in 
healthy vaccinated children. 
 
  
INTRODUCTION 
In the United Kingdom, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 
September 2006 as a 2+1 schedule for all infants at 2, 4 and 12 months alongside a 12-month 
limited catch-up for <2 year-olds [1]. The programme led to a rapid decline in invasive 
pneumococcal disease (IPD) and, since young children are the main carriers of S. pneumoniae and 
PCV7 reduces carriage acquisition [2], significant reductions in PCV7-type IPD were observed 
across all age-groups, with overall IPD rates falling by 34% [3]. From April 2010, PCV7 was 
replaced by a 13-valent PCV (PCV13) without any catch-up and, by 2013/14, IPD incidence had 
fallen by a further 32% because of continued reduction in PCV7-type IPD and a 69% reduction in 
PCV13-type IPD [4].  
The development of vaccine-serotype IPD in a PCV-immunised child (i.e. vaccine failure) is rare [5]. 
Although a number of studies have described children with PCV7 failure, little is known about 
PCV13 failure. Since individual pneumococcal serotypes have different propensities for 
invasiveness and disease, and since vaccine immunogenicity varies for the different serotypes, it is 
likely that the characteristics of children with PCV13 failure are different to those with PCV7 failure. 
This study aimed to describe the rate, vaccination status, serotype distribution, clinical 
characteristics and outcomes of children aged <5 years with PCV7 and PCV13 failure in England 
and Wales over an eight-year period. 
 
  
METHODS 
Public Health England (PHE) conducts enhanced national surveillance of IPD in England and Wales 
and, since PCV7 introduction, collected clinical and epidemiological information for all laboratory-
confirmed IPD cases in <5 year-olds [3]. Briefly, hospital laboratories routinely report clinically 
significant infections to PHE electronically and submit invasive pneumococcal isolates to the 
national PHE Reference Laboratory for confirmation and serotyping. As part of enhanced national 
surveillance, general practitioners (GPs) and hospital paediatricians for <5 year-olds with laboratory-
confirmed IPD completed a short questionnaire on vaccination history, known co-morbidities at the 
time of IPD, complications and outcomes. In the UK, children are actively called and immunised by 
their GPs, and their vaccinations documented in their individual electronic records. For this study, all 
children born since 04 September 2004 (i.e. including <2 year-olds eligible for the initial catch-up) 
with PCV failure diagnosed during 04 September 2006 to 03 September 2014 (i.e. 8-year period) 
were included. 
Definitions 
 IPD was defined as S. pneumoniae cultured from a normally sterile site or pneumococcal DNA 
detected in cerebrospinal fluid (CSF) or pleural fluid. Meningitis was defined as S. pneumoniae 
identified (culture/PCR) in the CSF or S. pneumoniae cultured from blood with radiological and/or 
clinical features of meningitis.  Lower respiratory tract (LRTI) was defined as S. pneumoniae 
identified in pleural/empyema fluid or in blood with a radiological and/or clinical diagnosis of 
pneumonia. Septicaemia was defined as S. pneumoniae cultured in blood with no clear focus of 
infection. Co-morbidity was defined as presence of a high-risk condition as defined in the Green 
Book on Immunisation [6]. For children with >1 IPD episode, only the first episode was included in 
the primary analysis; subsequent episodes are described separately.  
Of the cases eligible for PCV7 only, the vaccine failure group was composed of three cohorts aged 
<5 years at diagnosis: PCV7-type IPD in a child (i) ≥14 days after two doses in <12 month-olds 
(PCV7-PCV7), (ii) ≥7 days after a single PCV7 dose in ≥12 month-olds (PCV7 catch-up); or (iii) ≥7 
days after three PCV7 doses including the 12-month booster (PCV7-PCV7-PCV7). By definition, 
these cohorts could still be diagnosed even after PCV13 introduction if they only received PCV7, 
were diagnosed with PCV7-type IPD and were aged <5 years at diagnosis. The vaccine failure 
group that was eligible for ≥1 PCV13 dose also included three cohorts aged <5 years at diagnosis: 
IPD caused by the additional PCV13 serotypes (1, 3, 5, 6A, 7F and 19A) (i) ≥14 days after two 
doses in <12 month-olds (PCV13-PCV13); (ii) ≥7 days after PCV7 in infancy with a 12-month 
PCV13 booster (PCV13 catch-up); and (iii) ≥7 days after three PCV13 doses including the 12-
month booster (PCV13-PCV13-PCV13).  
Data Analysis 
Data were analysed using Stata™ v.11.0 (Statcorp, Texas) and are mainly descriptive. The 
denominator for the vaccine failure rate was calculated by multiplying the number of children aged 
<5 years who were eligible for a specific vaccine schedule nationally (www.statistics.gov.uk) with 
the vaccine coverage and the eligible time-period for that schedule. Childhood vaccine coverage for 
both PCV7 and PCV13 has remained consistently high (>90%) over the years 
(https://www.gov.uk/government/collections/immunisation) [7]. Categorical variables were described 
as percentages with binomial 95% confidence intervals (95% CI) and compared using the chi-
squared test or two-tailed Fisher’s Exact test. Continuous variables that did not follow a normal 
distribution were described as medians with interquartile ranges (IQR) and compared using the 
Mann-Whitney U test. Multivariable logistic regression was used to investigate relationships 
between variables using the largest group as the baseline and adjusting for age as a continuous 
variable, gender and co-morbidity status. The serotype distribution among vaccine failure cases 
were compared to overall laboratory-confirmed IPD cases in the same age group in the nearest 
complete epidemiological year before the introduction of the relevant PCV (i.e. 2005/06 for PCV7 
failures and 2009/10 for PCV13 failures). A p value of <0.05 was considered statistically significant; 
in Table 2, the Bonferroni correction was applied for multiple comparisons among PCV7 and PCV13 
serotypes.  
RESULTS 
Over the eight-year surveillance period (04 September 2006 to 03 September 2014), 163 PCV 
failure episodes were confirmed in 161 children aged <5 years from ten birth cohorts. Complete 
clinical questionnaires and responsible serotypes were available for all children.  
 
Types of failure 
Of the 161 children, one third (n=57, 35.4%) were exclusively PCV7 failures, including 12 after 
completing the 2+1 schedule (Table 1). After PCV13 introduction, there were 104 additional failures, 
including 28 after three PCV13 doses. Compared to PCV7 serotypes responsible for IPD prior to 
PCV7 introduction (2005/06 epidemiological year), serotypes 6B and 19F were significantly over-
represented while serotypes 4 and 14 were under-represented among PCV7 vaccine failures (Table 
2). Following PCV13 introduction, serotype 3 was significantly over-represented and serotype 7F 
under-represented among PCV13 vaccine failures when compared to PCV13 serotypes responsible 
for IPD during 2009/10 (Table 2). In 2013/14, eight serotypes contributed to 23 vaccine failure 
cases, including nine (39%) due to serotype 3, four (17%) serotype 1 and three each (13%) of 
serotypes 19A and 19F (Figure 1).  
Following the 2+0 schedule, although there were very few cases, serotype 19A failures clustered 
during the three months prior to the 12-month booster (Figure 2). This was not observed for any of 
the other PCV13 serotypes, including serotype 3. Additionally, of the 18 serotype 19A IPD cases 
diagnosed after 12 months of age, only two were in fully immunised children; the others were either 
in the PCV7-PCV7-PCV13 group (n=9) or developed IPD after their first birthday (5 of 7 cases 
diagnosed at 12-14 months of age) following a delay in receiving their 12-month booster. In 
contrast, 12/33 (36%) serotype 3 IPD cases after 12 months of age occurred in fully-immunised 
children, 16 in the PCV7-PCV7-PCV13 group and five in those with delayed 12-month booster. 
PCV7 failure rate after three doses was 0.19/100,000 person-years (95% CI, 0.10-0.33) and 
0.66/100,000 person-years (95% CI, 0.44-0.95) after three PCV13 doses (Table 1). The annual 
incidence of vaccine failure cases declined with time since PCV7 introduction, but this was less 
marked after PCV13 introduction (Figure 1). The increase in vaccine failure rates from 2010/11 was 
due to the inclusion of the additional PCV13 serotypes. Children with PCV13 failure were more 
likely to have been healthy (85% vs. 67%; aOR=2.8; 95% CI, 1.3-5.9; P=0.01), present with LRTI 
(58% vs. 21%; aOR, 4.6; 95% CI, 2.2-9.9; P<0.001) and develop empyema following LRTI (67% vs. 
8%; aOR=20.7; 95% CI, 2.4-175.2; P=0.005) compared to PCV7 failures (Table 3). PCV7 failures 
had increased odds of presenting with septicaemia compared to PCV13 failures (47% vs. 19%; 
aOR=3.2, 95% CI, 1.5-6.7; P=0.002). 
 
Clinical Presentation 
Overall, LRTI (n=72; 45%) was the most common clinical presentation (Table 3). Serotypes 3 
(n=28/72; 39%), 19A (n=15; 21%) and 1 (n=9; 13%) were responsible for most cases. Notably, 
28/38 (74%) serotype 3, 15/30 (50%) serotype 19A and 9/13 (69%) serotype 1 cases presented 
with LRTI. Forty-one of the 72 children (57%) with LRTI developed empyema, including 22/28 
(79%), 8/15 (53%) and 6/9 (67%) due to serotypes 3, 19A and 1, respectively. These same three 
serotypes were more likely to cause vaccine failure in healthy children than those with co-morbidity 
(Figure 3).  
Septicaemia was the second most common clinical presentation (n=47; 29%) and serotypes19F 
and 6B (11/47 each; 23%) were mainly responsible. Meningitis was diagnosed in 36 children (22%); 
of these, five (14%) had co-morbidities and 19A (7/36, 19%), 19F (6/36; 17%) and 6B (5/36; 14%) 
were the main responsible serotypes. 
 
IPD by Comorbidity status 
Overall, 35 (22%) cases had underlying co-morbidity, mainly malignancy/immunosuppression 
(16/161, 10%) or cardiac abnormalities (8/161, 5%); five children (3%) had >1 comorbidities. 
Children with co-morbidity were likely to be older (median age, 28 [IQR, 18-39] vs. 19 [IQR, 11-28] 
months; P=0.007) and present with septicaemia (20/35 [57%] vs. 27/126 [21%]; aOR=5.5, 95% CI, 
2.4-12.7; P<0.0001), but less likely to present with LRTI (9/35 [26%] vs. 63/126 [50%]; aOR=0.24, 
95% CI, 0.10-0.60; P=0.002). Serotype 6B (n=7; 20%), 23F (n=6; 17%) and 3 (n=5, 14%) were the 
main serotypes responsible; 6/10 (60%) serotype 23F and 3/6 (50%) serotype 18C, but only 5/38 
(13%) serotype 3, IPD cases occurred in children with co-morbidity. Conversely, only 3/30 (10%) 
serotype 19A, 1/13 (8%) serotype 1 and 1/5 (20%) serotype 7F occurred in children with 
comorbidity.  
 
Repeat episodes and case fatality 
One toddler with congenital hydrocephalus and a VP shunt suffered two episodes of serotype 6B 
meningitis, with the first episode occurring five months after a PCV7 catch-up dose. A second 
toddler with congenital deafness developed two episodes of serotype 4 meningitis after three PCV7 
doses, with the first episode occurring two weeks after cochlear implantation [2, 8]. CFR among 
vaccine failure cases was 4% (n=6; 95% CI, 1-8%) (Table 3). Five children had underlying co-
morbidity and one was healthy (5/35 [14%] vs. 1/126 [1%]; p<0.001).  
  
DISCUSSION 
In England and Wales, PCV failure was rare, with only 161 children diagnosed in ten birth cohorts 
diagnosed over eight years (<1/100,000 vaccinated person-years). Vaccine failure rates were higher 
after two PCV doses in infancy and lowest after completion of the recommended 3-dose schedule, 
most likely because of a combination of factors, including higher VE after 3 doses, lower incidence 
in older ages and more time for herd immunity effects after PCV introduction. PCV13-failure cases 
were more likely to be healthy and develop LRTI, while those with PCV7-failure were more likely to 
have co-morbidities and develop septicaemia. Only a third of PCV13-failure cases had co-morbidity, 
mainly immunosuppression and cardiac abnormality. Recurrent IPD was rare (two children) and 
case fatality rate was low (six children), both associated with underlying co-morbidity.  
Following three infant doses of the Haemophilus influenzae type b (Hib) conjugate vaccine, the 
vaccine failure rate was 2.2/100,000 UK children over six years and five months [9].  For the 
meningococcal group C (MenC) conjugate vaccine, only 53 vaccine failure cases were identified 
among <18 year-olds during the first four years after vaccine introduction [10]. Potential 
explanations for vaccine failure include the presence of underlying co-morbidities and waning 
antibodies after vaccination, which has been described for both Hib and MenC vaccine failures [9, 
10].  
In the UK, PCV7 introduction rapidly achieved high vaccine coverage, resulting in 98% and 93% 
lower IPD rates in PCV7-type IPD within four years in <2 year-olds and 2-4 year-olds, respectively 
[3]. Compared to serotypes causing IPD in the pre-PCV7 period, serotypes 6B and 19F were over-
represented among vaccine failure cases. These two serotypes had the lower antibody responses 
after infant immunisation [11], and the lowest serotype-specific vaccine effectiveness after PCV7 
introduction (49% and 70%, respectively) [12]. Others have also reported a predominance of these 
two serotypes among PCV7 failure cases, which were responsible for 59% of PCV7 failures in our 
cohort [13]. Co-morbidity prevalence in the published literature, relating almost exclusively to PCV7 
failures, ranged between 10-36%, which is in keeping with 15% in our cohort [5], with 
immunosuppression – mainly malignancy – and cardiac conditions predominating.  
After PCV13 introduction, serotype 3 was over-represented among vaccine failures. Low vaccine 
effectiveness for this serotype has been reported in England and Wales [14], although some 
protection was observed in the United States [15]. In infants, serotype 3 elicited the lowest post-
primary and post-booster antibody responses of the additional PCV13 serotypes [16]. It is estimated 
that very higher serum IgG concentrations (>2.83 µg/mL) are required for protect against disease 
compared to the internationally-accepted threshold of 0.35 µg/mL [14], which are rarely attained 
after vaccination [16]. On the other hand, although serotype 19A is immunogenic in infants [16], 
vaccine effectiveness against this serotype has been poor (62% after two infant doses, 67% after 
three doses including the 12-month booster). A higher correlate for protection (>1.0 µg/mL) has also 
been estimated for this serotype [14].  
In our cohort, the clustering of serotype 19A vaccine failure cases around the first birthday may 
indicate waning immunity after two infant priming doses, but this was not observed for any other 
serotype. Whether a three-dose priming schedule might reduce vaccine failure rates before the 12-
month booster by inducing higher post-primary immunisation antibody concentrations is 
questionable, but this would involve an additional ~700,000 doses to prevent around eight vaccine 
failure cases, annually.  
On the other hand, the vaccine failure cases diagnosed after 12 months of age in this same group 
highlights the importance of timely immunisation, especially for the booster dose. This dose is 
critical not only for individual protection but also to maintain herd protection through reduction in 
carriage.  
Another contributing factor was the single PCV dose from 12-months of age in the initial PCV7 
catch-up campaign and among those who received PCV7-PCV7-PCV13, when the latter vaccine 
was introduced. Here, two PCV doses from 12 months of age doses might have reduced vaccine 
failure rates but would have involved additional vaccination and immunisation visits during the 
catch-up campaign to prevent very few vaccine failure cases annually.  
Comparison of PCV7 with PCV13 vaccine failure cases identified several important differences. 
Children with PCV13 failure were more likely to be healthy and develop LRTI. During 2006-2010 
(after PCV7 introduction and before replacement with PCV13), we reported higher co-morbidity 
prevalence among children with PCV7-failure compared with cases in unvaccinated children due to 
the same serotypes. Moreover, IPD due to the additional PCV13 serotypes was associated with 
lower comorbidity (17% vs. 40%) and higher LRTI (58% vs. 20%) prevalence when compared to 
children with PCV7-type IPD [5]. This pattern was also observed for serotype 3 only, which is 
responsible for a third of vaccine failure cases in our PCV13 cohort. After PCV13 introduction, 19% 
of our PCV13 failure cases had comorbidity, compared to 9% among unvaccinated children with 
PCV13-type IPD prior to PCV13 introduction.5 Any additional benefit of offering extra PCV13 doses 
to children with comorbidities (e.g. using a 3+1 schedule) is are likely to be negligible given the 
small numbers of PCV13-failures overall (23 cases) and in those with co-morbidities (6 cases, 
including five in fully-immunised children) in 2013/14. Children with co-morbidities are also 
benefiting from the continuing indirect (herd) protection offered by the current programme 
Clinical Implications 
An important consideration for children with conjugate vaccine failure, especially those without 
known co-morbidities, is the possibility of an undiagnosed underlying immune deficiency. In addition 
to clinical risk factors, immunoglobulin deficiency has been described in those with Hib [17], but not 
MenC, vaccine failure [10]. In the UK, 11% of 172 children with IPD had transient IgG deficiency, 
which was only marginally below the lower limit for age [18]. We recently reported that, although a 
significant proportion of vaccinated children with vaccine-type IPD did not achieve protective 
antibody thresholds against the infecting serotype even after vaccination post-IPD, their IgG 
responses to the other vaccine serotypes remained intact, indicating that an underlying antibody 
deficiency was unlikely [19]. In a recent French study, however, 26/163 (16%) children with IPD had 
abnormal immunological investigations and 17 (10%) had a primary immunodeficiency, including 
MyD88 deficiency (n=1), complement C2/C3 deficiency (n=1), congenital asplenia (n=1) and 
Bruton’s disease (X-linked agammaglobulinaemia; n=1) [20]. In addition to MyD88, a number of rare 
primary immunodeficiencies associated with mutations in toll-like receptors (TLR), interleukin 
pathways (e.g. IRAK4) and NEMO genes have been associated with (often recurrent) invasive 
bacterial infections in early childhood, mostly due to S. pneumoniae [21]. The extent of 
immunological investigations for individual children with conjugate vaccine failure is likely to require 
careful clinical assessment, taking into account the family and past history of serious infections as 
well as the severity of IPD. An underlying immune deficiency is more likely in children who develop 
IPD after two years of age [20], and those with recurrent IPD [22], but has not been reported for 
children with PCV failure, possibly because this is such a rare event. 
In England and Wales, follow-up investigations in children with IPD were at the discretion of the 
attending clinician but, since the surveillance questionnaire was completed several weeks after the 
IPD episode, any immune deficiency identified after IPD would have been reported. It is also 
reassuring that second episodes and deaths among vaccine failure cases were rare.  
This study has strengths and limitations. The established IPD surveillance spanning more than two 
decades alongside a national reference laboratory service has ensured high case ascertainment 
and near-complete follow-up of laboratory-confirmed cases. We did not include children diagnosed 
by urinary pneumococcal antigen or blood pneumococcal PCR; neither test is offered by local 
hospital laboratories or the national reference laboratory because nasopharyngeal carriage can give 
false-positive results in young children colonised with Streptococcus pneumoniae [23]. We also do 
not collect detailed information on IPD cases in children after their fifth birthday. If PCV13-type IPD 
cases do start appearing in older children because of waning immunity, for example, these would be 
identified through the on-going national IPD surveillance. Finally, it was also not possible to 
compare vaccine failure rates between the two PCVs for several reasons, including non-
contemporaneous introduction of the two vaccines, differences in circulating serotypes prior to 
vaccine introduction, differential serotype-specific carriage rates, invasiveness of individual 
serotypes, serotype-specific vaccine immunogenicity and a catch-up programme for PCV7 only. 
Each vaccine, however, has been used for approximately four years and these results suggest that 
vaccine failure is more common for the additional PCV13 serotypes, especially serotype 3.  
CONCLUSIONS 
Most children with PCV13 failure were healthy, developed LRTI and survived their infection without 
long-term complications. The low prevalence of PCV7 failures after PCV13 introduction is 
reassuring and it is likely that PCV13 failures will also decline in the coming years. Given that most 
IPD cases are now due to non-PCV13 serotypes, there is an urgent need for serotype-independent 
subunit or whole-cell vaccines  to control this devastating disease [24]. 
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Figure 1. Incidence of pneumococcal conjugate vaccine (PCV) failure (A) by immunisation schedule 
and (B) due to individual serotypes by surveillance year (September to August of the following year) 
in England And Wales. Figure 1C depicts the proportional change in clinical presentation over the 8-
year surveillance period. 
 
Figure 2. Number of vaccine failure cases by age in months following a two-dose infant 
priming schedule with the 7-valent (PCV7) and the 13-valent (PCV13) pneumococcal 
conjugate vaccine (A) and by individual serotypes (B). Note that the vaccine failures in the first 
4 years (2006/7 to 2009/10) included only the 7 serotypes in PCV7, while those in the latter 4 years 
(2010/11 to 2013/14) included all the 13 serotypes in PCV13. 
 
Figure 3. Serotype distribution by co-morbidity status among children with pneumococcal 
conjugate vaccine failure in England and Wales, 2006-2014  
 
 
 
Table 1. Characteristics of children with vaccine failure in the cohort eligible for PCV7 and PCV13, England and Wales. 
 
All cases (%) 
PCV7 PCV13 
PCV7 catch-
up 
PCV7-PCV7 
PCV7-
PCV7-PCV7 
All PCV7 
Cases 
PCV13 catch-
up 
PCV13-PCV13 
PCV13-
PCV13-
PCV13 All PCV13 
Cases 
Immunised Cohort 
1 dose >12m 
only (catch- 
up) 
2 doses <12m 
only 
1 or 2 doses 
<12m + 12m 
booster 
2 doses PCV7 
<12m + 12m 
PCV13 booster  
2 doses <12m 
only 
2 doses 
<12m + 12m 
booster 
Total (%) 
161 
 
20 (12%) 
 
25 (16%) 
15* 
12 (7%) 
 
57 
 
35 (22%) 
 
41 (25%) 
28* 
28 (17%) 
 
104 
91* 
Immunised person-
years at risk 
17,513,442 1,747,843 1,390,792 6,364,742 9,503,378 2,085,286 1,656,249 4,268,529 8,010,064 
Vaccine failure rate 
per 100,000  person-
years at risk 
0.92 (0.78-1.07) 
 
1.14 (0.70-1.77) 
 
 
1.80 (1.16-2.65) 
1.08 (0.60-1.78)* 
 
0.19 (0.10-0.33)  
 
0.60 (0.45-0.78) 
 
1.68 (1.17-2.33) 
 
2.48 (1.78-3.36) 
1.69 (1.12-2.44)* 
0.66  (0.44-0.95) 
 
1.30 (1.06-1.57) 
 
Male Cases 90 (55%) 12 (60%) 17 (68%) 8 (67%) 37 (65%) 23 (66%) 18 (44%) 12 (43%) 53 (51%) 
Median age in 
months (IQR) 
20.0 (11.3-30.9) 25.6 (22.2-39.3) 10.0 (6.3-12.7) 38.3 (32.1-43.1) 21.0 (11.3-37.0) 29.7 (20.1-41.4) 10.0 (8.6-12.2) 23.9 (19.9-30.4) 19.9 (11.2-29.6) 
          
* In infants receiving two priming doses (2+0 schedule), only those vaccine failure cases diagnosed before 12 months of age were included in this 
analysis 
 
 
 
Table 2. Distribution of vaccine failure serotypes compared to the pre-vaccine baseline. Proportions of individual serotypes causing IPD in England 
and Wales during the epidemiological year prior to PCV introduction were compared using the 2-test against the proportion of IPD cases caused by the same 
serotypes in vaccinated children after PCV introduction. After applying the Bonferroni correction for multiple comparisons, p<0.007 was considered statistically 
significant for the PCV7 serotypes and p<0.003 for the PCV13 serotypes.  
 
Serotype  
Total  
cases by 
serotype 
Pre-PCV7 
serotypes 
among IPD 
cases 
2005/06 
PCV7 Pre-PCV13 
serotypes 
among IPD 
cases 
2009/10 
PCV13 
Total PCV7 
 
1 dose 
>12m only 
(catch up) 
2 doses 
< 12m 
only 
1 or 2 
doses 
<12m + 
12m 
booster 
Total PCV13 
2 doses 
PCV7 <12m 
+ 12m 
PCV13 
booster  
2 doses 
<12m 
only 
2 doses 
<12m + 
12m 
booster 
N=161 N=2,122 N=57 N=20 N=25 N=12 N=2,651  N=104 N=35 N=41 N=28 
4 2 (1%) 298 (14%) 2 (4%) - - 2 70 (3%) - - - - 
6B 23 (14%) 219 (10%) 19 (33%), P<0.001 9 9 1 72 (3%) 4 (4%) 2 - 2 
9V 5 (3%) 323 (15%) 5 (9%), 2 2 1 72 (3%) - - - - 
14 5 (3%) 646 (30%) 3 (5%), 1 2 - 72 (3%) 2 (2%) - 1 1 
18C 6 (4%) 145 (7%) 4 (7%) - 1 3 59 (3%) 2 (2%) - 1 1 
19F 22 (14%) 195 (9%) 15 (26%), P<0.001 4 9 2 69 (3%) 7 (7%) - 4 3 
23F 10 (6%) 296 (14%) 9 (16%) 4 2 3 70 (3%) 1 (1%) - - 1 
1 13 (8%)      457 (17%) 13 (11%) 7 2 4 
3 38 (24%)      376 (14%) 38 (37%), P<0.001 16 10 12 
5 1 (0.6)      9 (0.3%) 1 (1%) 1 - - 
6A 1 (0.6)      99 (4%) 1 (1%) - 1 - 
7F 5 (3%)      621 (23%) 5  (5%), P<0.001 - 3 2 
19A 30 (19%)      605 (23%) 30 (29%) 9 19 2 
Table 3. Characteristics of children with vaccine failure in the cohort eligible for PCV7 and 
PCV13, England and Wales. 
 
All 
cases  
PCV7 PCV13 
PCV7 
catch-up 
PCV7-
PCV7 
PCV7-
PCV7-
PCV7 
All PCV7 
cases 
PCV13 
catch-up 
PCV13-
PCV13 
PCV13-
PCV13-
PCV13 
All 
PCV13 
cases 
 
1 dose 
>12m 
only 
(catch 
up) 
2 doses 
< 12m 
only 
1 or 2 
doses 
<12m + 
12m 
booster 
2 doses 
PCV7 
<12m + 
12m 
PCV13 
booster 
2 doses 
<12m 
only 
2 doses 
<12m + 
12m 
booster 
Total cases 161  20  25  12 57 35 41 28 104 
Prematurity 
15 
(9%) 
1 (5%) 4 (16%) 1 (8%) 6 (11%) 5 (14%) 3 (7%) 1 (4%) 9 (9%) 
Any co-
morbidity 
35 
(22%) 
8 (40%) 5 (20%) 6 (50%) 
19 
(33%) 
5 (14%) 4 (10%) 7 (25%) 
16 
(15%) 
* 
Clinical Presentation 
     Meningitis 
36 
(22%) 
5 (25%) 7 (28%) 4 (33%) 
16 
(28%) 
2 (6%) 15 (37%) 3 (11%) 
20 
(19%) 
     LRTI 
72 
(45%) 
5 (25%) 5 (20%) 2 (17%) 
12 
(21%) 
28 (80%) 13 (32%) 
19 
(68%) 
60 
(58%) * 
     
Septicaemia 
47 
(29%) 
9 (45%) 12 (48%) 6 (50%) 
27 
(47%) 
4 (11%) 11 (27%) 5 (18%) 
20 
(19%) * 
     Other 6 (4%) 1 (5%) 1 (4%) - 2 4%) 1 (3%) 2 (5%) 1 (4%) 4 (4%) 
2nd episode 2 (1%) - - 1 (8.3) 1 (2%) - - 1 (4%) 1 (1%) 
Died 6 (4%) 1 (5%) 1 (4%) - 2 (4%) 2 (6%) 1 (2%) 1 (4%) 4 (4%)  
* P<0.01 (proportions were compared using the 2-test between cases eligible for PCV7 only and 
those eligible for ≥1 PCV13) 
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